ACHIEVE LIFE SCIENCES, INC. ACHV
Nasdaq · XNAS · stock · In Vitro & In Vivo Diagnostic Substances
Chart by TradingView
1/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$54.6M | — | -$49.5M | $21.5M |
| 2024 | — | -$39.8M | — | — | $20.9M |
| 2023 | — | -$29.8M | — | -$24.5M | -$1.4M |
| 2022 | — | -$42.4M | — | — | $8.3M |
| 2021 | — | -$33.2M | — | — | $28.0M |
| 2020 | — | -$14.7M | — | -$13.5M | $37.3M |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Source: SEC EDGAR filings · CIK 0000949858 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.